QUantoom Biosciences's CTO and an engineer setting-up the Ntensify™ midi in Andover, Boston

At Quantoom Biosciences, scientists, engineers, and clinicians are committed to solving some of the biggest challenges facing mRNA-based vaccines and therapeutics production.

January
2013

Launch of Univercells

In 2013, Univercells was created with the ambition to make biologics available and affordable to all.

January
2013

September
2020

Incubation within Univercells

Incubation of the “Quantoom” project within Univercells with the vision to reinvent mRNA production based on observations made during the COVID-19 pandemic and utilizing Univercells’ distinctive bioprocessing expertise.

September
2020

June
2021

Official launch of Quantoom Biosciences

The COVID-19 pandemic has underlined the desperate need for technological innovation in manufacturing to provide a simple, scalable way to make RNA. By lowering the barriers to RNA production, we allow our partners that have previously not considered exploring RNA-based vaccines and therapeutics, to gain access to RNA production capabilities and enter the market.

June
2021

July
2021

Collaboration with eTheRNA

Quantoom entered into a strategic collaboration to build an advanced, small footprint technology platform for the production of affordable RNA-based therapies, that can be used either within existing facilities or rapidly deployed to areas of urgent need.

July
2021

December
2021

Grants of $13.9 million to support the development of the mRNA platform

The company received grants from the Bill & Melinda Gates Foundation and the Walloon Region of Belgium for an amount of $7.5 million (€ 6.7 million), and $6.4 million (€ 5.7 million), respectively.

December
2021

June
2022

Agreement for the first African-owned Covid-19 vaccine

The collaboration between Univercells and Afrigen Biologics (hosting the World Health Organization’s Global mRNA Vaccine Technology Transfer Hub) will focus on the development of a novel mRNA vaccine that will drastically accelerate access to vaccination by using Quantoom’s mRNA production technology. Afrigen Biologics and Univercells will be supported in the collaboration by mRNA specialist eTheRNA.

June
2022

May
2023

Installation of the 1st Ntensify midi

Quantoom Biosciences announces the installation of its first Ntensify™ midi system for mRNA vaccine production in the GMP facility of Afrigen Biologics in Cape Town, South Africa. 

May
2023

September
2023

US R&D lab & showroom opening

Opening of a showroom in Andover, MA in the Boston area with a nucleic acid R&D laboratory as the foundation for the launch of Quantoom Biosciences’ activities in North America.

September
2023

March
2024

Launch of the Ntensify mano

Quantoom Biosciences announces the extension of the Ntensify™ product line with the launch of Ntensify™ mano, an mRNA kit containing mixes of reagents for mRNA production and purification for research use.

March
2024

Laboratory technicians discussion in the development laboratories of Quantoom Biosciences

To support our mission of removing the barriers to making accessible and affordable mRNA-based vaccines, our international team is composed of experts with competencies ranging from in-silico to in-vivo experimental studies and analytical tools. Our brilliant minds have strong and complementary backgrounds in molecular and structural biology, process development, equipment engineering, qualification and validation, product development, and more.

Quantoom has built a highly-skilled team of international experts to develop Ncapsulate™, our RNA formulation system. The team can manage the development, screening and optimization of lipid nanoparticle (LNP) and polymer-based formulations for RNA delivery. We can also provide physicochemical, in vitro and in vivo characterization, including biodistribution and immune challenge for prophylactic vaccine application of RNA delivery systems. We provide services for the development of the entire RNA formulation process and manufacturing system.

Laboratory technician in a development laboratory of Quantoom Biosciences
Ntensify™ midi in operation

Based on fundamental engineering principles, the idea is to intensify and introduce sequential-staggered production. This significantly reduces the footprint for easy transportation and optimization of cleanroom space. Manual steps are reduced which improves safety and product quality by advancing RNA production technologies, Quantoom Biosciences will drastically reduce production costs and improve the availability of life-saving biologics.

Our partnership with eTheRNA enables the transfer of materials and data necessary for the development of the Ntensify Maxi. Quantoom will be responsible for commercialization of the system worldwide with sales-related royalties payable to eTheRNA. International sales and distribution are expected to commence in 2023.

The Afrigen partnership paves the way for the development of the first-ever African-owned COVID-19 vaccine. Afrigen hosts the World Health Organization’s Global mRNA Vaccine Technology Transfer Hub and is working to facilitate the production of mRNA vaccines at over 15 designated manufacturing sites in LMICs across the world. The collaboration focuses on development of a novel mRNA vaccine using intellectual property from the collaboration partners, as well as developing new IP, to supercharge access to the vaccine.

Early 2023, Quantoom Biosciences entered into a public-private partnership with Immunewatch and the University of Antwerp. The goal of this project is to assess if a detailed analysis of the T-cell receptor response can be utilized to inform vaccine design and augment the vaccine development process. It is believed that the proposed methodology could reduce time and expenditures in the preclinical development process of vaccines. As a proof-of-concept, the team has chosen to work on a rabies vaccine candidate.

Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM)

The collaborative investment by Biotechnology and Biological Sciences Research Council (BBSRC), the Foreign, Commonwealth and Development Office (FCDO) and the Bill & Melinda Gates Foundation, totalling almost £40m, promotes a ‘one health’ approach towards improving the health and wellbeing of animals and humans on a global scale. The new Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) will bridge the gaps between research and expertise in process development and manufacturing.

The NucNanoFish project, led by ICRAD, has assembled a consortium of six partners, with highly complementary expertise to develop new vaccines to prevent fish viral diseases for sustainable aquaculture.

The consortium is composed of one company focused in nanodelivery of antigen and mRNA using LNP, four groups of fish immunovirologists / vaccinologists and Quantoom for the DNA production aspect.